Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1. Opus Genetics granted 240,000 stock options to new employees. 2. Options vest over four years; exercise price is $0.94. 3. Company focuses on gene therapies for inherited retinal diseases. 4. Lead candidate OPGx-LCA5 shows promising results in trials. 5. Additional therapies in pipeline include treatments for diabetic retinopathy.